Clinical Trials Browser

Neoplasms × dabrafenib × 1 year × Clear all

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT01682083 2026-04-21

COMBI-AD

Phase 3 Completed

870 enrolled 15 charts 1 FDA

Dermatologic

Melanoma, Neoplasms

NCT07440290 2026-02-27

DETERMINE

Phase 2/3 Not yet recruiting

30 enrolled

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT04418167 2025-09-03

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Phase 1 Suspended

71 enrolled

DermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Carcinoma, Anaplastic

Clinical Trials

TAPUR

COMBI-AD

DETERMINE

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations